Fibricor Injection contains Ibutilide (NA), a potent antiarrhythmic agent used primarily for the rapid conversion of recent onset atrial fibrillation and atrial flutter to normal sinus rhythm. Ibutilide works by prolonging the action potential duration and refractory period in cardiac tissues, thereby stabilizing the heart's electrical activity and preventing abnormal rapid heartbeats. Administered intravenously under strict medical supervision, Fibricor Injection is typically reserved for patients who require immediate restoration of normal heart rhythm due to symptomatic arrhythmias. The onset of action is rapid, making it an effective choice in acute settings. However, its use necessitates continuous cardiac monitoring due to the risk of proarrhythmia, including torsades de pointes, a potentially life-threatening ventricular tachyarrhythmia. Dosage and administration must be carefully tailored based on patient response and clinical condition, with attention to electrolyte imbalances and other contraindications. Fibricor Injection should be used cautiously in patients with structural heart disease, electrolyte disturbances, or prolonged QT interval. Overall, Fibricor Injection is a valuable therapeutic option for managing atrial arrhythmias when rapid cardioversion is clinically indicated, contributing to improved cardiac function and symptom relief.